GHK-Cu vs minoxidil for hair: the evidence side by side
Reviewed 22 sourcesPublished by PepVault
GHK-Cu vs minoxidil for hair: the trials and FDA labels behind minoxidil, the small studies and lab work behind GHK-Cu, and what oral minoxidil adds.

- Last reviewed
- Sources
- 22
- Questions
- 10
- Compounds
- 1
The short answer
Minoxidil has the trials. In a 48-week trial of 393 men, 5% minoxidil regrew more hair than 2% or placebo, women's trials found the same, and it is sold over the counter. GHK-Cu has no scalp hair-loss trial of its own and has never been tested against minoxidil in people. Its hair data are one small eyebrow trial, mixtures, cells and rodents.
Evidence: Minoxidil: large randomized placebo-controlled trials in men and women, and FDA over-the-counter approval. GHK-Cu for hair: one small eyebrow trial, combination products, and cell and rodent studies.

Which has more evidence, GHK-Cu or minoxidil?
Minoxidil, by a wide margin. It has placebo-controlled trials with hundreds of men and women, and the FDA lets it be sold without a prescription126. GHK-Cu, a copper peptide used in skin care, has been tested on its own on human hair once: on eyebrows, in 18 people15.
| At a glance | Minoxidil on the scalp | GHK-Cu on the scalp |
|---|---|---|
| What it is | A blood-pressure drug that regrows hair on the scalp620 | Three amino acids holding a copper ion; a cosmetic ingredient |
| US status for hair loss | Approved over the counter: 2% and 5% solution, 5% foam678 | Not approved for hair loss |
| Largest hair trial | 393 men, 48 weeks, against 2% and placebo1 | 18 adults, eyebrows only, 12 weeks15 |
| Trials in women | 381 women for 48 weeks; 404 women for 24 weeks24 | None on the scalp |
| Tested against the other | Not in people; once in mice12 | Not in people; once in mice12 |
| Common side effects | Itching, scalp irritation, unwanted facial hair126 | Few reported; no serious effects in the eyebrow trial15 |
| When results show | From 2 to 4 months in men, 3 to 6 months in women on the foam, per the labels67 | No label; the eyebrow trial read its result at 12 weeks15 |
| If you stop | Hair loss begins again, per the labels67 | Not studied |

GHK-Cu for skin, from the wrinkle trials to injection, has its own guide: pepvault.app/guides/ghk-cu-skin-and-hair.

How does each one work on the hair follicle?
A follicle cycles between a growth phase (anagen) and a resting phase (telogen). In pattern hair loss follicles shrink and the growth phase shortens, so hairs come back thinner.
Minoxidil pushes the other way. In animal studies it shortens the resting phase so follicles start growing sooner, and it may lengthen the growth phase and enlarge the follicle; it probably acts the same way in people9. As a tablet it lowers blood pressure by opening potassium channels in blood vessel walls. Whether that channel explains the hair effect had not been shown when that 2004 review was written9.
GHK-Cu is three amino acids, glycine, histidine and lysine, holding one copper ion. Its proposed hair action runs through the dermal papilla, the cells at the base of the follicle that steer its growth: a close relative, AHK-Cu, made those cells multiply and scalp follicles lengthen in a dish10. That is tissue outside the body, not a person's scalp.

Peptide SkySee GHK-Cu as a molecule53 peptides as a night sky in 3D. Each star opens into its molecule, one bead per amino acid, with the measured shape where one exists.Open the Peptide SkyWhat did the minoxidil trials find?
Five randomized trials (pepvault.app/glossary/randomized-controlled-trial) carry most of the weight, counting hairs in a marked patch of scalp against a placebo (pepvault.app/glossary/placebo), the same liquid or foam without minoxidil, or the other strength.
| Trial | Who | What was compared | What they found |
|---|---|---|---|
| Olsen 20021 | 393 men aged 18 to 49, 48 weeks | 5% vs 2% solution vs placebo, twice daily | 5% beat 2% and placebo; 45% more regrowth than 2% at week 48 |
| Lucky 20042 | 381 women aged 18 to 49, 48 weeks | 5% vs 2% solution vs placebo, twice daily | Both strengths beat placebo on hair counts; 5% beat 2% only on the women's own rating of benefit |
| Olsen 20073 | 352 men aged 18 to 49, 16 weeks | 5% foam vs placebo foam | More hair on the foam (p < 0.0001) |
| Bergfeld 20164 | 404 women, 24 weeks | 5% foam once daily vs placebo foam | 9.1 more hairs per square centimetre than placebo at week 24 |
| Blume-Peytavi 20165 | 322 women, read at 24 weeks | 5% foam once daily vs 2% solution twice daily | About 24 more hairs per square centimetre than at the start, on each; the test for 'no worse' missed its preset bar |
The labels put it plainly. On the men's 5% products, results may show at 2 months or take 4, and they are for the top of the scalp, not a receding hairline6. On the women's once-a-day 5% foam, results may show at 3 months or take 67. The women's 2% label: after 8 months, 19% of women reported moderate regrowth, against 7% on placebo8. Every label says regrowth lasts only with continued use678.
What is the hair evidence for GHK-Cu?
Only the first of these tested GHK-Cu itself on people. Read the third column first.
| Study | What was tested | Who or what | What they found |
|---|---|---|---|
| Bo 202615 | 2% GHK-Cu serum on one eyebrow, placebo serum on the other, twice daily | 18 healthy adults aged 18 to 40, 12 weeks | More and thicker eyebrow hairs on the GHK-Cu side; no serious side effects |
| Lee 201613 | GHK joined to 5-aminolevulinic acid, no copper, on the scalp | 45 men with pattern hair loss, 6 months, vs placebo | Hair count rose more than on placebo; no difference in thickness or length |
| Kapoor 201814 | Scalp injections of six growth factors and peptides, copper tripeptide-1 among them | 1,000 patients, no control group | Less shedding and more hair; GHK-Cu's share can't be separated |
| Liu 202312 | 2% GHK-Cu in a microemulsion vs 5% minoxidil vs saline | Shaved healthy mice, 6 per group, 21 days | The authors report regrowth beyond minoxidil's |
| Uno and Kurata 199311 | PC1031, a synthetic copper-binding peptide, not GHK-Cu | Fuzzy rats | Larger follicles, an effect the authors likened to topical minoxidil's |
| Pyo 200710 | AHK-Cu, a related copper tripeptide | Human scalp follicles and papilla cells in a dish | Follicles grew longer; papilla cells multiplied |
The eyebrow trial is well designed, randomized and double-blind (pepvault.app/glossary/double-blind) with one brow as the other's control, but it had 18 people, appeared in conference proceedings PubMed does not index, and treated brows, not a thinning scalp15. A 2026 systematic review of GHK-Cu on its own in aesthetic medicine found 20 studies, 18 of them preclinical, and only 2 randomized trials, both on skin16. A second 2026 review, of peptide products for hair loss in people, found 14 trials and rated formulas containing GHK, combinations with other peptides among them, at grade B on an A-to-C scale22.
Species note: the Liu, Uno and Pyo results are from mice, rats (pepvault.app/glossary/in-vivo) and human tissue in a dish (pepvault.app/glossary/in-vitro): copper peptides acting on follicles, not a serum regrowing a person's hair.
Has anyone tested GHK-Cu against minoxidil?
Not in people. The one direct comparison is in mice: in shaved mice, 6 per group, a 2% GHK-Cu microemulsion regrew more fur than 5% minoxidil over 21 days, by the authors' account12. Shaved healthy mice are a model of regrowth after shaving, not of pattern hair loss.
A claim circulates online that a 2022 study found a 0.5% GHK-Cu serum raised hair count 22% in 16 weeks and beat 3% minoxidil; other pages cite a 2006 trial and a 2023 trial of 114 people. On November 20, 2026 we searched PubMed and ClinicalTrials.gov for GHK-Cu and copper peptides in hair loss and found none of them. Until a paper can be read, those numbers have no source.
What about oral minoxidil?
Low-dose oral minoxidil is off-label (pepvault.app/glossary/off-label): a doctor prescribes a tablet approved only for severe high blood pressure, at a usual 10 to 40 mg a day, with a boxed warning (pepvault.app/glossary/boxed-warning) written for those patients20. The hair studies use lower amounts: the men's trial below tested 5 mg a day.
The trials so far put it level with topical. In a 24-week randomized trial in 90 men, 5 mg by mouth daily did not beat 5% topical twice daily on hair density17. A 2025 meta-analysis (pepvault.app/glossary/meta-analysis) of four randomized trials and 279 patients found the same hair density and thickness on oral and topical, with extra body and facial hair about twice as common on oral18. In the largest safety study, 1,404 patients, 15.1% had extra hair growth, 1.7% lightheadedness and 1.3% fluid retention; 1.7% stopped over a side effect19.
In 2025, 43 hair-loss dermatologists from 12 countries agreed on who suits it and what to check first21. It is a decision made with a doctor, and no trial has compared it with GHK-Cu.
What side effects does each one have?
On the scalp, minoxidil's usual effects are itching and irritation, a little more often on 5% than on 2%12. In women on 5%, extra hair outside the scalp (hypertrichosis) was more common than on 2% or placebo2. In the eyebrow trial, GHK-Cu caused no serious side effects or allergic reactions, and the 2016 scalp trial of GHK with 5-aminolevulinic acid recorded no adverse events1315.
Commonly reported: a few weeks of extra shedding in the first two months of minoxidil, which users describe as settling; an itchy or flaky scalp on solutions; a faint blue tint and occasional mild tingling from GHK-Cu serums.
When to get help The minoxidil labels say to stop and ask a doctor if chest pain, a racing heartbeat, faintness or dizziness, sudden weight gain, or swollen hands or feet appear67.
Can you use GHK-Cu and minoxidil together?
No trial has tested the pairing. The minoxidil labels say not to use it if you use other medicines on the scalp67; a cosmetic serum isn't a medicine, and a pharmacist can say whether a particular product counts.
How do you tell if it's working?
- Before the first use, photograph the top and the parting in the same light and angle, hair dry and combed the same way.
- Write down the start date, the product and its strength.
- Use it the same way every day; the labels say regrowth only lasts with continued use6.
- Compare new photos with the first ones at month 2 and month 4 (month 3 and month 6 on the women's foam), the points the labels name67.
- If there is no regrowth by month 4 on the men's products or month 6 on the women's foam, the labels say to stop and ask a doctor67.

PepVault's side-effects log keeps each entry with its date, severity and a note, so an itchy week or a shedding phase sits on the calendar beside your start date. Log it in PepVault
Where to read more
- The GHK-Cu library page, pepvault.app/peptides/ghk-cu, with its side effects, how long it takes to work and legal status pages.
- Study pages for GHK-Cu, from pepvault.app/research/ghk-cu-maquart-1993 to pepvault.app/research/ghk-cu-mokhtar-2026.
- Peptides for skin, side by side: pepvault.app/peptides/for/skin.
- Next guide: GHK-Cu for skin and hair, what's measured.
Sources
- Olsen EA et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002. PubMed 12196747
- Lucky AW et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004. PubMed 15034503
- Olsen EA et al. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2007. PubMed 17761356
- Bergfeld W et al. A phase III, multicenter, parallel-design clinical trial to compare the efficacy and safety of 5% minoxidil foam versus vehicle in women with female pattern hair loss. J Drugs Dermatol. 2016. PubMed 27391639
- Blume-Peytavi U et al. Efficacy and safety of once-daily minoxidil foam 5% versus twice-daily minoxidil solution 2% in female pattern hair loss: a phase III, randomized, investigator-blinded study. J Drugs Dermatol. 2016. PubMed 27391640
- DailyMed. Men's Rogaine Extra Strength (minoxidil 5%) topical solution, drug facts label (Kenvue, Nov 2026). dailymed.nlm.nih.gov
- DailyMed. Women's Rogaine (minoxidil 5%) topical foam, drug facts label (Nov 2024). dailymed.nlm.nih.gov
- DailyMed. Women's Rogaine (minoxidil 2%) topical solution, drug facts label (Sep 2024). dailymed.nlm.nih.gov
- Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol. 2004. PubMed 14996087
- Pyo HK et al. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 2007. PubMed 17703734
- Uno H, Kurata S. Chemical agents and peptides affect hair growth. J Invest Dermatol. 1993. PubMed 8326148
- Liu T et al. Thermodynamically stable ionic liquid microemulsions pioneer pathways for topical delivery and peptide application. Bioact Mater. 2023. PubMed 38026438
- Lee WJ et al. Efficacy of a complex of 5-aminolevulinic acid and glycyl-histidyl-lysine peptide on hair growth. Ann Dermatol. 2016. PubMed 27489425
- Kapoor R, Shome D. Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth: safety and efficacy evaluation in a first-in-man pilot clinical study. J Cosmet Laser Ther. 2018. PubMed 29482481
- Bo SL et al. The efficacy of 2% copper peptide (GHK-Cu) serum for eyebrow hypotrichosis: a randomized, double-blind, vehicle-controlled, split-face comparative study. Procedia of Multidisciplinary Research. 2026;4(5). so09.tci-thaijo.org
- Mokhtar J et al. The regenerative potential of GHK-Cu in aesthetic medicine. Aesthet Surg J. 2026. PubMed 42619529
- Penha MA et al. Oral minoxidil vs topical minoxidil for male androgenetic alopecia: a randomized clinical trial. JAMA Dermatol. 2024. PubMed 38598226
- Sobral MVS et al. Efficacy and safety of oral minoxidil versus topical solution in androgenetic alopecia: a meta-analysis of randomized clinical trials. Int J Dermatol. 2025. PubMed 39425514
- Vañó-Galván S et al. Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients. J Am Acad Dermatol. 2021. PubMed 33639244
- DailyMed. Minoxidil tablets, prescribing information (American Health Packaging, Aug 2026). dailymed.nlm.nih.gov
- Akiska YM et al. Low-dose oral minoxidil initiation for patients with hair loss: an international modified Delphi consensus statement. JAMA Dermatol. 2025. PubMed 39565602
- Joerg L, Zafar K, Jagdeo J. Peptides for hair growth and treatment of hair loss and alopecia: a systematic review. J Drugs Dermatol. 2026. PubMed 42976838
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.